Bioventus vs Novocure
Novocure reported revenue of $655 million in fiscal 2025, 1.2 times Bioventus' $568 million in fiscal 2025. Bioventus' revenue fell 0.9% in its latest year, and Novocure's grew 8.3%. Bioventus had an operating margin of 9.5%, against -23.5% at Novocure. Free cash flow was $72 million at Bioventus and −$76 million at Novocure.
Side by side
| Bioventus | Novocure | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $568M | $655M |
| Revenue growth | −0.9% | 8.3% |
| Revenue growth a year, last 5 years | 12.1% | 5.8% |
| Gross margin | 68.3% | 74.5% |
| Operating margin | 9.5% | −23.5% |
| Net margin | 4.0% | −20.8% |
| Free cash flow | $72M | −$76M |
| Free cash flow margin | 12.7% | −11.6% |
| Return on capital | 11.1% | −33.0% |
| Net debt to EBITDA | 2.5x | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 6.8% | 3.4% |
| Last close | $10.66 | $11.83 |
| P/E at the last close | 13.3× | — |
| Insider trades, last 12 months | — | sold $2.9 million |
| Piotroski F-score | 8 of 9 | 4 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
BioventusNovocure
Operating margin
Percent of revenue
BioventusNovocure
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BioventusNovocure
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Bioventus and Novocure pages.